Femasys (FEMY) AI Stock Analysis

• Market Cap: $30.23M
• Dividend Yield: N/A
• Average Volume (3M): 416.65K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.64
• Revenue Growth: 61.97%
• EPS Growth: -6.89%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.23
• Shares Outstanding: 32,526,160
• 10 Day Avg. Volume: 376,125
• 30 Day Avg. Volume: 416,646
• PEG Ratio: -0.02
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: -0.32
• Enterprise Value/Gross Profit: -1.59
• Enterprise Value/Ebitda: 0.03
• 1Y Price Target: $7.00
• Price Target Upside: 652.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 44 Neutral
• Price Target: $1.00 ▲(7.53%Upside)

The overall stock score reflects significant financial and operational challenges, balanced by some positive corporate developments. The financial instability and potential delisting are major concerns, whereas recent regulatory approvals offer potential growth opportunities. Investors should weigh these factors carefully.

Positive Factors

Market Expansion

FemaSeed is now being offered in more than 60 clinics across the U.S., which could allow for quick patient access.

Partnerships

Strategic distribution partnerships in Spain are set to drive the initial FemBloc launch, with additional EU partnerships expected soon.

Regulatory Approval

FemBloc system receives EU approval, clearing it for commercial launch in select markets, starting with Spain.

Negative Factors

Commercial Performance

Overall sales in 1Q25 were $0.34M, which were much lower than our estimate of $1.5M.

Market Competition

Greater-than-expected commercial competition for any of the company’s programs, given other treatments on the market or in development.

Revenue Estimates

We have lowered our 2025 revenue based on the slower than expected ramp up, and now estimate revenues of $5.3M compared to our prior estimate of $10M.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

How the Company Makes Money

Femasys makes money primarily through the development and commercialization of its medical devices and technologies. The company's revenue streams are mainly derived from the sale of its proprietary products, such as FemBloc, a non-surgical permanent birth control solution, and FemVue, an infertility diagnosis product. Femasys may also engage in strategic partnerships and licensing agreements with healthcare providers and distributors to expand the reach of its products, contributing to its revenue. The company's earnings are influenced by the demand for its innovative solutions in women's health and its ability to successfully navigate regulatory approvals and market competition.

Femasys Financial Statement Overview

Summary

Femasys is facing financial headwinds with persistent losses and cash flow issues. Revenue growth is overshadowed by operational inefficiencies and financial instability. Improving financial health and achieving profitability are crucial for future sustainability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.70M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	1.13M	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-18.54M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-21.11M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	0.00	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	0.00	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	7.67M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	1.44M	10.14M	9.40M	1.65M	2.24M	59.42M
Stockholders Equity	2.00M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow
Free Cash Flow	-20.50M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.64M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-854.21K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	6.48M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.93 is above the 20-day moving average (MA) of 0.90, below the 50-day MA of 1.00, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 28.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	75 Outperform	$13.13M	1.15	7.10%	―	-0.19%	-18.41%
Sector *	59 Neutral	HK$15.37B	5.69	-7.44%	4.08%	11.55%	-28.15%
FEMY	44 Neutral	$30.23M	―	-239.87%	―	61.97%	-6.89%
RVP	44 Neutral	$19.69M	―	-25.89%	―	-16.05%	-195.28%
MLSS	44 Neutral	$53.36M	―	-88.36%	―	-9.13%	30.04%
HBIO	43 Neutral	$19.59M	―	-138.80%	―	-14.41%	-549.88%
POAI	42 Neutral	$7.59M	―	-504.16%	―	-31.31%	49.27%

Femasys Corporate Events

Femasys Enters Purchase Agreement with Alumni Capital

On June 30, 2025, Femasys Inc. entered into a Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its common stock over a specified period. This agreement provides Femasys with flexibility in financing, contingent on market conditions and trading prices, while ensuring compliance with regulatory requirements and ownership limitations.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Gains Regulatory Approvals in Australia and New Zealand

On July 1, 2025, Femasys Inc. announced the achievement of regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. These approvals mark a significant milestone in expanding global access to Femasys’ innovative infertility solutions, validating the clinical value of their platform and creating meaningful commercial opportunities. This development reinforces Femasys’ commitment to providing accessible, first-line infertility solutions, addressing critical gaps in care for women struggling with infertility.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Approves Director Elections and Share Increase

On June 25, 2025, Femasys Inc. held its Annual Meeting of Stockholders, where approximately 59.41% of the total outstanding shares were represented. During the meeting, stockholders approved the election of two Class I directors, an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 3,000,000, and ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Gains European Approval for FemBloc System

On June 25, 2025, Femasys Inc. announced the European CE mark approval of FemBloc, the first non-surgical permanent birth control system. This approval marks a significant milestone for the company, allowing the FemBloc system to be marketed across the European Economic Area. The FemBloc system, which offers a safer and more cost-effective alternative to traditional surgical sterilization, is set to be commercially available in Spain and other select European countries. This development underscores Femasys’ commitment to providing innovative solutions in women’s health and is expected to enhance its industry positioning and impact stakeholders positively.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Appoints Kelley Nicholas as Chief Commercial Officer

On June 17, 2025, Femasys Inc. announced the appointment of Kelley Nicholas as Chief Commercial Officer to lead the U.S. commercialization of fertility products and expand global partnerships. Ms. Nicholas, with over 25 years of industry experience, is expected to drive revenue growth and strengthen Femasys’ position in women’s health. The company also granted her an option to purchase 100,000 shares of common stock as an inducement for her employment.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Announces Public Offering and Private Placement

On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares of common stock at $0.85 per share. The company also initiated a concurrent private placement with existing institutional stockholders and certain directors and officers, raising a total of approximately $4.5 million before expenses. The proceeds are intended for commercial expansion, product development, and general corporate purposes. Additionally, Femasys agreed to establish a $10 million equity line of credit with Alumni Capital LP by June 30, 2025, with potential penalties if not completed.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Receives Nasdaq Delisting Notice for Low Market Value

On May 19, 2025, Femasys received a notice from Nasdaq indicating that the market value of its listed securities had fallen below the required $35 million for continued listing on the Nasdaq Capital Market. The company has until November 17, 2025, to regain compliance, or it may face delisting. Femasys plans to actively monitor its market value and explore options to meet the requirement, although there is no assurance of success.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.